<DOC>
	<DOCNO>NCT00287820</DOCNO>
	<brief_summary>The primary objective study ass whether chronic treatment olanzapine five-month period produce significant increase abnormality glucose level . The main secondary objective evaluate whether increase glucose level rate glucose abnormality differs Olanzapine Risperidone treatment period . Additional secondary objective study investigate similar question respect glycohemoglobin , triglycerides measure glucose lipid metabolism . We hypothesize Olanzapine inferior Risperidone extent increase primary outcome measure serum glucose , secondary measure glycohemoglobin , insulin lipid .</brief_summary>
	<brief_title>Comparative Effects Chronic Treatment With Olanzapine Risperidone Glucose Lipid Metabolism</brief_title>
	<detailed_description>In on-going study progress use extensive battery assessment investigate ) fasting level glucose lipid baseline monthly 5 month treatment , b ) glucose tolerance test investigate glucose insulin abnormality glucose load baseline study treatment , c ) effect treatment olanzapine risperidone post prandial glucose metabolism fatty meal ( detailed body proposal ) . Recent study show increased postprandial lipidemia important feature many patient type 2 diabetes atherosclerosis . In addition biochemical measure , also assess clinical effect ( PANSS CGI rating ) side-effects ( weight gain , appetite , somnolence , EPS TD ) . The specific plan call inpatient tertiary care hospital randomly assign olanzapine risperidone , use stratified random assignment procedure , treat five month either olanzapine risperidone . We estimate enroll sample approximately 50-55 patient obtain 46 acceptable complete case ( specify proposal ) . On basis preliminary result prior ongoing study predict significant increase glucose abnormality baseline chronic treatment olanzapine significant difference development glucose abnormality patient patient treated olanzapine risperidone . Additional measure investigate include : comparison olanzapine risperidone glucose lipid response fatty meal , ghrelin change response fatty mean , CRP IL-6 , thyroid prolactin response five month treatment two drug .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Diagnosis Schizophrenia schizoaffective psychosis 1865 year age Currently treat oral antidiabetic insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>diabetes</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>glucose</keyword>
	<keyword>insulin</keyword>
	<keyword>lipid</keyword>
	<keyword>IL-6</keyword>
	<keyword>prolactin</keyword>
</DOC>